Patents by Inventor Sanjay Sonar
Sanjay Sonar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10000544Abstract: A process for production of insulin or insulin analogs by expression of Insulin or Insulin analogs through an expression vector in a host cell is provided. The expression vector includes a leader peptide of SEQ ID NO 3; a nucleotide sequence encoding an affinity tag linked to C-terminal end or N terminal end of nucleotide sequence of the leader peptide; and a nucleotide sequence encoding for a cleavage site ligated to nucleotide sequence of the leader peptide through nucleotide sequence encoding the affinity tag.Type: GrantFiled: July 31, 2014Date of Patent: June 19, 2018Assignee: BIOGENOMICS LIMITEDInventors: Archana Krishnan, Sanjay Sonar, Damodar Thappa
-
Patent number: 9803207Abstract: An expression vector for production of a recombinant protein in a host cell is provided. The expression vector includes a nucleotide sequence of Sequence ID No 2 encoding for a leader peptide of sequence ID No 3.Type: GrantFiled: July 31, 2014Date of Patent: October 31, 2017Assignee: BIOGENOMICS LIMITEDInventors: Archana Krishnan, Sanjay Sonar, Damodar Thappa
-
Publication number: 20160186190Abstract: An expression vector for production of a recombinant protein in a host cell is provided. The expression vector includes a nucleotide sequence of Sequence ID No 2 encoding for a leader peptide of sequence ID No 3.Type: ApplicationFiled: July 31, 2014Publication date: June 30, 2016Inventors: Archana KRISHNAN, Sanjay SONAR, Damodar THAPPA
-
Publication number: 20160168226Abstract: A process for production of insulin or insulin analogues by expression of Insulin or Insulin analogues through an expression vector in a host cell is provided. The expression vector includes a leader peptide of SEQ ID NO 3; a nucleotide sequence encoding an affinity tag linked to C-terminal end or N terminal end of nucleotide sequence of the leader peptide; and a nucleotide sequence encoding for a cleavage site ligated to nucleotide sequence of the leader peptide through nucleotide sequence encoding the affinity tag.Type: ApplicationFiled: July 31, 2014Publication date: June 16, 2016Inventors: Archana KRISHNAN, Sanjay SONAR, Damodar THAPPA
-
Publication number: 20160159853Abstract: A machine or apparatus for refolding a protein of interest produced recombinantly in a host cell in form of inclusion bodies is provided. The apparatus includes an inclusion bodies (IB) solubilisation tank to solubilise the inclusion bodies; a plurality of refolding vessels or reactors arranged in series to receive a refolding feed; a first tank connected to the IB solubilisation tank to hold diafiltration buffer or agent; a first diafiltration cartridge having at least one permeate end and one retentate end, connected to the IB solubilisation tank, through a first retentate end to feed the refolding feed to the IB solubilisation tank; a second tank, connected to the first permeate end of the diafiltration cartridge to receive and recycle the refolding buffer and each of the refolding vessels, for supplying refolding buffer or agent to each of the refolding vessels.Type: ApplicationFiled: July 18, 2014Publication date: June 9, 2016Inventors: Sanjay SONAR, Archana KRISHNAN, Nikhil GHADE, Faiza SHAIKH
-
Publication number: 20160039868Abstract: A process for obtaining a refolded recombinant protein from an unfolded recombinant protein present in inclusion bodies isolated from wet cells harvested from a cell culture is provided. The process includes a) reducing the inclusion bodies by treating the inclusion bodies with a reducing buffer, to obtain reduced inclusion bodies; b) obtaining stable first intermediate state I1 of the unfolded recombinant protein present in the reduced inclusion bodies; and c) refolding the stable first intermediate state I1 of the unfolded recombinant protein, present in the reduced inclusion bodies, in refolding buffer to obtain a second intermediate state I2 that folds to produce the refolded recombinant protein.Type: ApplicationFiled: March 21, 2014Publication date: February 11, 2016Applicant: BioGenomics LimitedInventors: Archana KRISHNAN, Sanjay SONAR, NIKHIL GHADE, FAIZA SHAIKH
-
Publication number: 20150376228Abstract: A process of refolding a recombinant protein from inclusion bodies (IBs) formed inside a host cell, is provided. The process includes homogenising a wet cells slurry to obtain a cell lysate; incubating the cell lysate with a reducing agent to obtain a reduced cell lysate; isolating reduced IBs from the reduced cell lysate to obtain isolated IBs; solubilising the isolated IBs with a denaturing agent to obtain solubilised IBs; and subjecting the solubilised IBs to a unit process of refolding to obtain a refolded recombinant protein.Type: ApplicationFiled: February 21, 2014Publication date: December 31, 2015Applicant: BioGenomics LimitedInventors: Archana KRISHNAN, Sanjay SONAR, NIKHIL GHADE, FAIZA SHAIKH
-
Publication number: 20070172849Abstract: The invention is directed to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives, or substances recognized by the protein synthesizing machinery. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent,protein from other components of the translation system. The invention also comprises proteins prepared using misaminoacylated tRNAs which can be utilized in pharmaceutical compositions for the treatment of diseases and disorders in humans and other mammals, and kits which may be used for the detection of diseases and disorders.Type: ApplicationFiled: October 30, 2006Publication date: July 26, 2007Inventors: Kenneth Rothschild, Jerzy Olejnik, Sanjay Sonar
-
Publication number: 20070148680Abstract: The invention is directed to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives, or substances recognized by the protein synthesizing machinery. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent protein from other components of the translation system. The invention also comprises proteins prepared using misaminoacylated tRNAs which can be utilized in pharmaceutical compositions for the treatment of diseases and disorders in humans and other maninials, and kits which may used for the detection of diseases and disorders.Type: ApplicationFiled: December 14, 2006Publication date: June 28, 2007Inventors: Kenneth Rothschild, Sanjay Sonar, Jerzy Olejnik
-
Publication number: 20070020643Abstract: This invention relates to agents and conjugates that can be used to detect and isolate target components from complex mixtures such as nucleic acids from biological samples, cells from bodily fluids, and nascent proteins from translation reactions. Agents comprise a detectable moiety bound to a photoreactive moiety. Conjugates comprise agents coupled to substrates by covalent bounds which can be selectively cleaved with the administration of electromagnetic radiation. Targets substances labeled with detectable molecules can be easily identified and separated from a heterologous mixture of substances. Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered. Using photocleavable molecular precursors as the conjugates, label can be incorporated into macromolecules, the nascent macromolecules isolated and the label completely removed.Type: ApplicationFiled: January 5, 2006Publication date: January 25, 2007Applicant: The Trustees of Boston UniversityInventors: Kenneth Rothschild, Sanjay Sonar, Jerzy Olejnik
-
Publication number: 20060275750Abstract: This invention relates to agents and conjugates that can be used to detect and isolate target components from complex mixtures such as nucleic acids from biological samples, cells from bodily fluids, and nascent proteins from translation reactions. Agents comprise a detectable moiety bound to a photoreactive moiety. Conjugates comprise agents coupled to substrates by covalent bounds which can be selectively cleaved with the administration of electromagnetic radiation. Targets substances labeled with detectable molecules can be easily identified and separated from a heterologous mixture of substances. Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered. Using photocleavable molecular precursors as the conjugates, label can be incorporated into macromolecules, the nascent macromolecules isolated and the label completely removed.Type: ApplicationFiled: February 28, 2006Publication date: December 7, 2006Applicant: The Trustees of Boston UniversityInventors: Kenneth Rothschild, Sanjay Sonar, Jerzy Olejnik
-
Publication number: 20060024704Abstract: The invention is directed to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives, or substances recognized by the protein synthesizing machinery. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent protein from other components of the translation system. The invention also comprises proteins prepared using misaminoacylated tRNAs which can be utilized in pharmaceutical compositions for the treatment of diseases and disorders in humans and other mammals, and kits which may be used for the detection of diseases and disorders.Type: ApplicationFiled: June 6, 2005Publication date: February 2, 2006Inventors: Kenneth Rothschild, Jerzy Olejnik, Sanjay Sonar
-
Publication number: 20050074748Abstract: This invention relates to agents and conjugates that can be used to detect and isolate target components from complex mixtures such as nucleic acids from biological samples, cells from bodily fluids, and nascent proteins from translation reactions. Agents comprise a detectable moiety bound to a photoreactive moiety. Conjugates comprise agents coupled to substrates by covalent bounds which can be selectively cleaved with the administration of electromagnetic radiation. Targets substances labeled with detectable molecules can be easily identified and separated from a heterologous mixture of substances. Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered. Using photocleavable molecular precursors as the conjugates, label can be incorporated into macromolecules, the nascent macromolecules isolated and the label completely removed.Type: ApplicationFiled: September 8, 2003Publication date: April 7, 2005Inventors: Kenneth Rothschild, Sanjay Sonar, Jerzy Olejnik